<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290210</url>
  </required_header>
  <id_info>
    <org_study_id>URC102KR</org_study_id>
    <nct_id>NCT02290210</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients</brief_title>
  <official_title>A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in
      gout patients with hyperuricemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2014</start_date>
  <completion_date type="Actual">August 31, 2015</completion_date>
  <primary_completion_date type="Actual">December 2, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trend of serum uric acid reduction and trend of serum uric acid levels</measure>
    <time_frame>weekly for 3weeks</time_frame>
    <description>Frequency of patients with serum uric acid level reduced to &lt; 6.0 mg/dL and &lt; 5.0 mg/dL at each measurement</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo x 2weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URC102 0.25mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25mg URC102 x 2weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URC102 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5mg URC102 x 2weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URC102 1.0mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1.0mg URC102 x 2weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URC102 2.0mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2.0mg URC102 x 2weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URC102 0.25mg</intervention_name>
    <arm_group_label>URC102 0.25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URC102 0.5mg</intervention_name>
    <arm_group_label>URC102 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URC102 1.0mg</intervention_name>
    <arm_group_label>URC102 1.0mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>URC102 2.0mg</intervention_name>
    <arm_group_label>URC102 2.0mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with gout

        Exclusion Criteria:

          -  Participated in other clinical study within 12 weeks prior to enrollment, and received
             an investigational product (including placebo)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>JW Pharmaceutical</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-dong</state>
        <zip>137-864</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

